实用肝脏病杂志
實用肝髒病雜誌
실용간장병잡지
JOURNAL OF CLINICAL HEPATOLOGY
2013年
4期
310-313
,共4页
唐长华%李志彬%刘芳%洪可%刘颖%徐德翠
唐長華%李誌彬%劉芳%洪可%劉穎%徐德翠
당장화%리지빈%류방%홍가%류영%서덕취
乙型肝炎%肝衰竭%血浆置换%预测模型
乙型肝炎%肝衰竭%血漿置換%預測模型
을형간염%간쇠갈%혈장치환%예측모형
Hepatitis B%Liver failure%Plasma exchange%Predictive models
目的应用终末期肝病模型(MELD)、MELD-Na联合公式(MELD-Na)、MESO指数(MESO)、integrated MELD整合公式(iMELD)、MELDNa评分系统(MELDNa)评估慢加急性乙型肝炎肝衰竭患者在血浆置换(PE)治疗后短期预后。方法在122例慢加急性乙型肝炎肝衰竭入院24小时内进行 MELD、MELD-Na、MESO、iMELD、MELDNa评分,并随访3个月。应用受试者工作特征曲线(ROC)下面积(AUC)判断五个模型的预测能力。结果在3个月末,PE治疗组患者病死率为43.24%(16/37),与非PE治疗组55.65%(49/85)比,差异无统计学意义(x2=1.466, P=0.143);在PE治疗组,五种模型AUC分别为0.667、0.690、0.670、0.702和0.673,差异无统计学意义,仅iMELD的AUC>0.7,有一定的临床价值,而在非PE治疗组分别为0.901、0.916、0.906、0.876和0.910,差异无统计学意义,PE治疗组与非PE组AUC的比较均具统计学差异,MELD(Z=0.2087,P<0.05)、MELD-Na(Z=0.1971,P<0.05)、MESO (Z=0.2094,P<0.05)、iMELD(Z=0.155,P<0.05)、MELDNa(Z=0.2094<0.05);在PE治疗组,五种模型预测的正确率分别为72.97%、70.30%、75.78%、72.93%和75.68%,差异无统计学意义(x2=0.389,P=0.983),在非PE治疗组分别为83.53%、87.06%、82.35%、78.82%和84.71%,差异无统计学意义(x2=2.266,P=0.687),PE治疗组与非 PE治疗组之间相比较,其中MELD、MESO、iMELD、MELDNa均无统计学意义(分别为x2=1.818,P=0.178;x2=0.727,P=0.394;x2=0.499, P=0.480;x2=1.442,P=0.233),而仅MELD-Na具统计学意义(x2=4.916,P=0.027)。结论五种评分模型对非PE治疗的慢加急性乙型肝炎肝衰竭患者短期预后判断均有非常好的预测价值,而在PE治疗的慢加急性乙型肝炎肝衰竭患者,除iMELD对短期预后判断有临床应用价值外,其余四种模型评估患者短期预后的能力较差。
目的應用終末期肝病模型(MELD)、MELD-Na聯閤公式(MELD-Na)、MESO指數(MESO)、integrated MELD整閤公式(iMELD)、MELDNa評分繫統(MELDNa)評估慢加急性乙型肝炎肝衰竭患者在血漿置換(PE)治療後短期預後。方法在122例慢加急性乙型肝炎肝衰竭入院24小時內進行 MELD、MELD-Na、MESO、iMELD、MELDNa評分,併隨訪3箇月。應用受試者工作特徵麯線(ROC)下麵積(AUC)判斷五箇模型的預測能力。結果在3箇月末,PE治療組患者病死率為43.24%(16/37),與非PE治療組55.65%(49/85)比,差異無統計學意義(x2=1.466, P=0.143);在PE治療組,五種模型AUC分彆為0.667、0.690、0.670、0.702和0.673,差異無統計學意義,僅iMELD的AUC>0.7,有一定的臨床價值,而在非PE治療組分彆為0.901、0.916、0.906、0.876和0.910,差異無統計學意義,PE治療組與非PE組AUC的比較均具統計學差異,MELD(Z=0.2087,P<0.05)、MELD-Na(Z=0.1971,P<0.05)、MESO (Z=0.2094,P<0.05)、iMELD(Z=0.155,P<0.05)、MELDNa(Z=0.2094<0.05);在PE治療組,五種模型預測的正確率分彆為72.97%、70.30%、75.78%、72.93%和75.68%,差異無統計學意義(x2=0.389,P=0.983),在非PE治療組分彆為83.53%、87.06%、82.35%、78.82%和84.71%,差異無統計學意義(x2=2.266,P=0.687),PE治療組與非 PE治療組之間相比較,其中MELD、MESO、iMELD、MELDNa均無統計學意義(分彆為x2=1.818,P=0.178;x2=0.727,P=0.394;x2=0.499, P=0.480;x2=1.442,P=0.233),而僅MELD-Na具統計學意義(x2=4.916,P=0.027)。結論五種評分模型對非PE治療的慢加急性乙型肝炎肝衰竭患者短期預後判斷均有非常好的預測價值,而在PE治療的慢加急性乙型肝炎肝衰竭患者,除iMELD對短期預後判斷有臨床應用價值外,其餘四種模型評估患者短期預後的能力較差。
목적응용종말기간병모형(MELD)、MELD-Na연합공식(MELD-Na)、MESO지수(MESO)、integrated MELD정합공식(iMELD)、MELDNa평분계통(MELDNa)평고만가급성을형간염간쇠갈환자재혈장치환(PE)치료후단기예후。방법재122례만가급성을형간염간쇠갈입원24소시내진행 MELD、MELD-Na、MESO、iMELD、MELDNa평분,병수방3개월。응용수시자공작특정곡선(ROC)하면적(AUC)판단오개모형적예측능력。결과재3개월말,PE치료조환자병사솔위43.24%(16/37),여비PE치료조55.65%(49/85)비,차이무통계학의의(x2=1.466, P=0.143);재PE치료조,오충모형AUC분별위0.667、0.690、0.670、0.702화0.673,차이무통계학의의,부iMELD적AUC>0.7,유일정적림상개치,이재비PE치료조분별위0.901、0.916、0.906、0.876화0.910,차이무통계학의의,PE치료조여비PE조AUC적비교균구통계학차이,MELD(Z=0.2087,P<0.05)、MELD-Na(Z=0.1971,P<0.05)、MESO (Z=0.2094,P<0.05)、iMELD(Z=0.155,P<0.05)、MELDNa(Z=0.2094<0.05);재PE치료조,오충모형예측적정학솔분별위72.97%、70.30%、75.78%、72.93%화75.68%,차이무통계학의의(x2=0.389,P=0.983),재비PE치료조분별위83.53%、87.06%、82.35%、78.82%화84.71%,차이무통계학의의(x2=2.266,P=0.687),PE치료조여비 PE치료조지간상비교,기중MELD、MESO、iMELD、MELDNa균무통계학의의(분별위x2=1.818,P=0.178;x2=0.727,P=0.394;x2=0.499, P=0.480;x2=1.442,P=0.233),이부MELD-Na구통계학의의(x2=4.916,P=0.027)。결론오충평분모형대비PE치료적만가급성을형간염간쇠갈환자단기예후판단균유비상호적예측개치,이재PE치료적만가급성을형간염간쇠갈환자,제iMELD대단기예후판단유림상응용개치외,기여사충모형평고환자단기예후적능력교차。
Objective To evaluate the short-term prognosis by different predictive models in patients with hepatitis B-induced acute-on-chronic liver failure (ACLF)treated with plasma exchange (PE) or non-plasma ex-change (non-PE),including model for end-stage liver disease (MELD),MELD-Na formula (MELD-Na),the MESO index (MESO)and integrated IMELD formula (iMELD). Methods One hundred and twenty-two inpatients with hepatitis B virus-associated ACLF were evaluated by MELD, MELD-Na,MESO,iMELD and MELDNa within 24 hours of administration and were followed up for 3 months. The area under the receiver operating characteristic curve (AUC) was used to evaluate the predictive ability of these five models. Results At the end of 3 months, the mortality in PE group were 43.24%(16/37),which was not statistically significantly different (x2=1.466,P>0.05) from that (57.65%,49/85) in non-PE group;In PE group,the AUC of five models were 0.667,0.690,0.670,0.702 and 0.673,respectively,and the differences were not statistically significant;Only the AUC of iMELD was greater than 0.7 and had a clinical value; In non-PE group,the AUC of five models were 0.901,0.916,0.906,0.876 and 0.910, respectively,and these differences were not statistically significant;However,the AUC of each of five models was significantly different between PE group and non-PE group,i.e. MELD(Z=0.2087,P<0.05),MELD-Na (Z=0.1971, P<0.05),MESO(Z=0.2094,P<0.05),iMELD(Z=0.155,P<0.055) and MELDNa(Z=0.2094<0.05);The accuracy rates in PE group were 72.97%,70.30%,75.68%,72.93% and 75.68%,respectively and there were no significant differ-ence (x2=0.389,P=0.983);The accuracy rates in non-PE group were 83.53%,87.06%,82.35%,78.82%,84.82% and 84.71%,respectively,which were not significantly different(x2=2.266,P=0.687);The differences in the accuracy rates of the four predictive models (MELD,MESO,iMELD and MELDNa) between PE group and non-PE group were not statistically significantly different (x2=1.818,P=0.178;x2=0.727,P=0.394;x2=0.499,P=0.480;x2=1.442,P=0.233,re-spectively),only of one(MELD-Na) reached statistical significance(x2=4.916,P=0.027). Conclusions The models of MELD,MELD-Na,MESO,iMELD and MELDNa have better predictive value on predicting short-term prognosis in non-PE-treated patients with hepatitis B virus-associated ACLF,but in PE-treated patients only iMELD has.